Guggenheim analyst Yatin Suneja initiated InflaRx initiated with a Buy rating and $65 price target, citing his view that early data from lead asset IFX-1 indicate that it could be superior to the current standard of care, Humira, in its lead indication of hidradenitis suppurativa.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.